Loading…

Evaluation of the Active Targeting of Melanin Granules after Intravenous Injection of Dendronized Nanoparticles

The biodistribution of dendronized iron oxides, NPs10@D1_DOTAGA and melanin-targeting NPs10@D1_ICF_DOTAGA, was studied in vivo using magnetic resonance imaging (MRI) and planar scintigraphy through [177Lu]­Lu-radiolabeling. MRI experiments showed high contrast power of both dendronized nanoparticles...

Full description

Saved in:
Bibliographic Details
Published in:Molecular pharmaceutics 2018-02, Vol.15 (2), p.536-547
Main Authors: Bordeianu, C, Parat, A, Piant, S, Walter, A, Zbaraszczuk-Affolter, C, Meyer, F, Begin-Colin, S, Boutry, S, Muller, R. N, Jouberton, E, Chezal, J.-M, Labeille, B, Cinotti, E, Perrot, J.-L, Miot-Noirault, E, Laurent, S, Felder-Flesch, D
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The biodistribution of dendronized iron oxides, NPs10@D1_DOTAGA and melanin-targeting NPs10@D1_ICF_DOTAGA, was studied in vivo using magnetic resonance imaging (MRI) and planar scintigraphy through [177Lu]­Lu-radiolabeling. MRI experiments showed high contrast power of both dendronized nanoparticles (DPs) and hepatobiliary and urinary excretions. Little tumor uptake could be highlighted after intravenous injection probably as a consequence of the negatively charged DOTAGA-derivatized shell, which reduces the diffusion across the cells’ membrane. Planar scintigraphy images demonstrated a moderate specific tumor uptake of melanoma-targeted [177Lu]­Lu-NPs10@D1_ICF_DOTAGA at 2 h post-intravenous injection (pi), and the highest tumor uptake of the control probe [177Lu]­Lu-NPs10@D1_DOTAGA at 30 min pi, probably due to the enhanced permeability and retention effect. In addition, ex vivo confocal microscopy studies showed a high specific targeting of human melanoma samples impregnated with NPs10@D1_ICF_Alexa647_ DOTAGA.
ISSN:1543-8384
1543-8392
DOI:10.1021/acs.molpharmaceut.7b00904